Glycated haemoglobin (HbA 1c ), a marker of average glycaemia during the previous six to eight weeks, is a predictor of microvascular complications in diabetic individuals. However, the role of HbA 1c as a predictor of macrovascular complications (e.g. myocardial infarction or stroke) in these patients is not clearly defined. In contrast, new evidence suggests that HbA 1c can predict the risk of cardiovascular disease in the general population. The potential applications of this test in vascular disease prevention are discussed.
Introduction
Glycated haemoglobin (HbA 1c ), a marker of average glycaemia, is a predictor of microvascular complications in diabetic individuals.
1,2 However, it is not yet clear whether the HbA 1c is an indicator of the risk of the macrovascular complications associated with diabetes mellitus. [1] [2] [3] In addition, the concentration of this longterm index of glycaemia has recently been shown to predict cardiovascular disease (CVD) risk in individuals without diabetes. 3 This is an important finding because the comprehensive assessment of vascular risk will improve the targeting of preventive treatment. 
Limitations of HbA 1c measurement
Haemoglobin is separated initially as HbA 0 . This fraction is further separated into the following sub-fractions: HbA 1a1 , HbA 1a2 , HbA 1b and HbA 1c . Glucose is the carbohydrate in HbA 1c . Although the term glycated haemoglobin denotes total HbA 1 , HbA 1c assays are the predominant way of estimating 'long-term' glycaemic control. 4, 5 The normal life span of red blood cells (RBC) is 120 days. During this period the process of glycation takes place. However, recent glycaemia has the greatest influence on HbA 1c values 6 . Thus, approximately 50% of the total HbA 1c value results from glycation of Hb over the previous one month. 5 Overall, HbA 1c is a marker of average glycaemia during the previous six to eight weeks. 4, 5 There are "fast" or "slow" glycators of haemoglobin. This effect probably depends on the variability of RBC survival time. 7 This means that the value of HbA 1c tends to remain stable in the same person but it may vary considerably between individuals with the same degree of glucose impairment. For example, in those with the same degree of impaired glucose tolerance (IGT), HbA 1c values can fluctuate between 4% and 6% (typical reference range: 3.9 -6.1 %). 8, 9 Other limitations include the inaccuracy of HbA 1c assays in patients with abnormal haemoglobins or haemolytic diseases. In conclusion, the evidence suggests but does not confirm a role for HbA 1c as a predictor of CVD in the diabetic population. As far as macrovascular complications are concerned, diabetic patients are more likely to benefit from tight blood pressure control and the modification of the other major risk factors (e.g. dyslipidaemia and smoking) than from improved glycaemic control.
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HbA 1c and CVD risk in non-diabetic individuals
Several studies assessed the relationship between HbA 1c values and the risk of vascular disease. 3, [14] [15] [16] [17] [18] [19] [20] [21] [22] The European Prospective Investigation of Cancer and Nutrition study 3 (EPICNorfolk) included 4662 men (aged 45 -79 years) from the general population. They were followed up between 1995 and 1999. The primary endpoints were CVD, ischaemic heart disease (IHD) and all cause mortality. Since the EPIC-Norfolk study included only men, a gender-dependent relationship between HbA 1c and CVD could not be assessed. This is an important question that still needs to be answered. Thus, a recent meta-analysis 22 (10 prospective studies) revealed that compared to non-diabetic individuals, the relative risk of IHD was higher for diabetic women (2.58) than for diabetic men (1.85). This gender-based difference in risk was significant (p = 0.045).
These results of the EPIC-Norfolk study are in accordance with a combined analysis of the Whitehall, the Paris Prospective and the Helsinki Policemen studies.
14 Similarly, in the Framingham study, the risk of IHD showed a continuous increase across the spectrum of non-diabetic glucose tolerance 15 . Moreover, in two prospective studies, 16, 17 HbA 1c was a predictor of CVD in non-diabetic individuals. However, these two studies 16 
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Drugs and HbA 1c
Improved glycaemic control in diabetic individuals (Type 1 and 2) is clearly necessary to reduce the risk of microvascular complications. 1, 2 However, an added benefit may be that this policy will also result in a reduction in macrovascular complications. Similarly, in non-diabetic individuals the benefit from improved insulin sensitivity (as represented by 'lower' HbA 1c values) could be a reduction in CVD risk 3 . It follows that drugs that improve insulin sensitivity may provide an additional benefit. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] Fibrates are useful in mixed dyslipidaemias and they may also exert a small beneficial effect on insulin sensitivity. 23, 24, 25 One fibrate, gemfibrozil, significantly reduced (22 %; p = 0.006) the risk of vascular events in a secondary prevention trial that included diabetic individuals (at least 25% of the trial population) and patients with the features of the insulin resistance syndrome. 26 Statins (e.g. pravastatin and simvastatin) reduce the risk of vascular events in diabetic individuals and in those with impaired fasting glucose (IFG) (reviewed in reference 31). This benefit can be attributed to improving the lipid profile. 31 However, a recent study showed that simvastatin (compared with cholestyramine) improved 24hr albumin excretion and diastolic blood pressure in diabetic individuals independently of changes in low density lipoprotein cholesterol (LDL) levels. 32 Another study has shown that atorvastatin decreased insulin resistance in noninsulin dependent (Type 2) diabetic patients. 33 Clearly more research is required to define the role of statins in diabetic individuals and patients with IFG. Antihypertensive agents (e.g. doxazosin)
that increase insulin sensitivity may also be useful in these patient populations. 27, 28 There is also evidence showing that hormone replacement therapy (HRT) improves long-term glucose homeostasis (as indicated by HbA 1c measurements). 30 However, this finding requires confirmation.
Whether improving insulin sensitivity also influences plasma fibrinogen levels remains to be established 29 . However, such an effect could be important because fibrinogen is an independent and powerful predictor of vascular risk.
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The use of HbA 1C as a predictor of cardiovascular risk: Future prospects There is still a need to confirm that HbA 1c measurements can predict the risk of macrovascular events in both diabetic and non-diabetic individuals. The need to use HbA 1c measurements to assess cardiovascular risk in non-diabetic individuals may lead to the development of ultrasensitive assays. This is because small changes in this variable (possibly below an HbA 1c value of 5%) may be relevant (see comments, above, regarding the EPIC-Norfolk study 3 ).
It will also be necessary to assess if HbA 1c is a stronger and more costeffective predictor of cardiovascular risk than making a diagnosis of IGT or IFG using simple glucose measurements. A fasting glucose is currently recommended as part of the assessment of cardiovascular risk.
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However, for screening purposes, the need for fasting may be a disadvantage for glucose measurement but not when using HbA 1c assays.
Glycation of proteins and atherosclerosis
Whether glycaemia and/or the glycosylation by-products contribute to the pathogenesis of the cardiovascular complications in diabetic and nondiabetic individuals has not yet been clarified 5 . Although a detailed discussion of this topic is beyond the scope of this review it is of interest that the glycation of various lipoproteins [e.g. LDL and lipoprotein (a)] has been implicated in the pathogenesis of vascular disease. 35, 36 In addition, glycated human oxyHb inhibited nitric oxide (NO)-mediated vasorelaxation of human blood vessels. 37 A detailed discussion of the prognostic value of microalbuminuria in diabetic and non-diabetic individuals is beyond the scope of this review. However, it is worth mentioning that microalbuminuria is more likely to represent established endothelial dysfunction [38] [39] [40] [41] [42] rather than to be an early predictor of vascular risk like minimally raised HbA 1c levels. 3 The presence of established vascular damage might also explain why the predictive power of microalbuminuria can be more significant than that of HbA 1c levels. 3, [39] [40] [41] [42] Nevertheless, there is evidence of an association between microalbuminuria and HbA 1c measurements in diabetic and non-diabetic individuals. [38] [39] [40] [41] [42] Tight glycaemic control may retard the progression of microalbuminuria in patients with Type 2 diabetes. 42 However, this effect is not necessarily associated with less deterioration of glomerular function or a decrease in the risk of macrovascular events 42 . Microalbuminuria can be induced in patients with peripheral vascular disease after exercise. 43 However, the effect of different levels of HbA 1c on this phenomenon has not been investigated. 
Conclusion
